Journals / Genel Tıp Dergisi / 2006 / Cilt: 16 - Sayı: 1

A general evaluation on primary hepatic malignities

Karaciğerin primer malign tümörlerine genel bakış

Pages
43–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The closely follow-up of patients having the predisposing disorders for primary hepatic malignities can yield an increase in the rates of early diagnosis and curative treatment modalities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The prevalences of primary hepatic malignities increase due to increasead hepatitis C infection, alcohol abuse and obesity.
📊
Key Findings & Data:We examined recently published articles in order to prepare a review on primary hepatic malign tumors.
💡
Conclusion & Impact:Conclusion: The closely follow-up of patients having the predisposing disorders for primary hepatic malignities can yield an increase in the rates of early diagnosis and curative treatment modalities.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Karsinom · hepatosellüler · Kolanjiokarsinom

Abstract

Objective: The prevalences of primary hepatic malignities increase due to increasead hepatitis C infection, alcohol abuse and obesity. We examined recently published articles in order to prepare a review on primary hepatic malign tumors. Main findings: Hepatocellular carcinoma and cholangiocellular carcinoma are the most common primary malignant tumors of the liver. HCC develops at patients with chronic parenchymal liver diseases. More efficient treatments such as resection and transplantation can be performed when HCC is diagnosed at an early stage. Therefore the following of the cases having risk factors for development of HCC is important. Fibro-lameller carcinoma can also occur at individuals without predisposing hepatic disorders. Cholangiocellular carcinoma originates from biliary ductal epitelium. Primary sclerosing cholangitis, clonorchiasis and thorotrast are most common risk factors for cholangiocellular carcinoma. Conclusion: The closely follow-up of patients having the predisposing disorders for primary hepatic malignities can yield an increase in the rates of early diagnosis and curative treatment modalities.

Özet

Amaç: Artan hepatit C enfeksiyonu, alkolizm ve obeziteye bağlı olarak karaciğerin primer malign tümörlerinin prevalansı giderek artmaktadır. Konuya ilişkin son literatürleri de inceleyerek primer hepatik maligniteler üzerine genel bir değerlendirme yapmayı amaçladık. Ana bulgular: Hepatosellüler karsinoma (HCC) ve kolanjiyosellüler karsinoma, primer malign hepatik tümörlerin en sık görülenleridir. HCC, kronik parankimal karaciğer hastalığı zemininde ortaya çıkar. Parsiyel hepatektomi ve transplantasyon gibi etkin tedaviler, ancak erken dönemde uygulanabilir. Bu nedenle risk grubunu oluşturan hastaların yakın takibi önemlidir. Fibrolameller karsinoma, normal karaciğerde de gelişebilmektedir. Kolanjiosellüler karsinoma, bilier duktal hücrelerden köken alır; primer sklerozan kolanjit, clonorchiasis ve thorotrast başlıca risk faktörleridir. Sonuç: Primer karaciğer kanserleri için risk grubuna giren hastaların yakın takibi, erken teşhis ve etkin tedavilerin uygulanabilirliğini artırmaktadır.

🔖

Cite This Article

NAZLIGÜL, Y., UZUNKÖY, A. (2006). A general evaluation on primary hepatic malignities. Genel Tıp Dergisi, Cilt: 16 - Sayı: 1, 43–48. https://ajindex.com/articles/224967

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: An overview. Asian Pac J Cancer Prev 2004;5:118-25
  2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005-14
  3. Ökten A, Demir K, Kaymakoğlu S, Özdil S, Dinçer D, Durakoğlu Z ve ark. Karaciğer sirozunda hepatosellüler karsinoma sıklığı ve etiyolojisi. Güncel Gastroenteroloji 2001;5:293-7
  4. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15 Suppl: E25-30
  5. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) Gut 2000;46:420-6
  6. Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36:1134-6
  7. Bailey MA, Brunt EM. Hepatocellular carcinoma: Predisposing conditions and precursor lesions. Gastroenterol Clin N Am 2002;31:641-62
  8. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis:incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50
  9. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S87-96
  10. Karakılçık AZ, Zerin M, Arslan O, Nazlıgül Y, Vural H. Effects of vitamin C and E on liver enzymes and biochemical parameters of rabbits exposed to aflatoxin B1. Vet Human Toxicol 2004;46:190-2
  11. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23:405-9
  12. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S79-86
  13. Polio J, Enriquez RE, Chow A, Wood WM, Atterbury CE. Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol 1989;11:220-4
  14. Cheng WS, Govindarajan S, Redeker AG. Hepatocellular carcinoma in a case of Wilson's disease. Liver 1992;12:42-5
  15. Jansen PL. Non-alcoholic steatohepatitis. Eur J Gastrenterol Hepatol 2004;16:1079-85
  16. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: A nove